Relation of exhaled nitric oxide levels to development of bronchopulmonary dysplasia

May, Carl; Williams, Olivia; Milner, Anthony; Peacock, Janet L.; Rafferty, Gerrard F.; Hannam, Simon; Greenough, Anne

doi:10.1136/adc.2008.146589

Cited by 28 publications

(40 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, 5-AIQ significantly inhibited the expression of iNOS, which is known to mediate the production of proinflammatory nitric oxide (NO) associated with the initiation and maintenance of different experimental and clinic pathologies including lung disease. Overproduction of NO leads to oxidative stress is one cause of cell death and tissue damage that characterizes a number of pathologies (Hesslinger et al, 2009;May et al, 2009). Second, 5-AIQ treatment downregulated levels of COX-2 mRNA, a protein shown to increase levels of a central mediator of inflammation, PGE2 (Sun et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

The role of poly(ADP-ribose) polymerase-1 inhibitor in carrageenan-induced lung inflammation in mice

Ahmad

Zoheir

Ansari

et al. 2015

Molecular Immunology

View full text Add to dashboard Cite

Increasing indication is unveiling a role for poly(ADP-ribose) polymerase (PARP)-1 in the regulation of inflammatory/immune responses. The aim of the present study was to determine the potential anti-inflammatory effects of PARP-1 inhibitor 5-aminoisoquinolinone (5-AIQ) to explore the role of PARP-1 inhibitor in a mouse model of carrageenan-induced lung inflammation. A single dose of 5-AIQ (1.5mg/kg) was administered intraperitoneally (i.p.) 1h before λ-carrageenan (Cg) administration. We assessed the effects of 5-AIQ treatment on CD25(+), GITR(+), CD25(+)GITR(+), IL-17(+) and Foxp3(+) cells which were investigated using flowcytometry in pleural exudates and heparinized blood. We also evaluated mRNA expressions of IL-6, TNF-α, IL-1β, IL-10, CD11a, l-selectin (CD62L), ICAM-1, MCP-1, iNOS and COX-2 in the lung tissue. We further examined the effects of 5-AIQ on the key mediators of inflammation, namely COX-2, STAT-3, NF-kB p65, PARP-1, IkB-α and IL-4 protein expression in the lung tissue using western blotting. The results illustrated that the numbers of T cell subsets, IL-17(+) cytokine levels were markedly increased and Foxp3(+) production decreased in the Cg group. Furthermore, Cg-induced up-regulation of adhesion molecules, pro-inflammatory mediators and chemokine expressions. Western blot analysis revealed an increased protein expressions of COX-2, STAT-3 NF-kB p65 and PARP-1 and decreased IkB-α and IL-4 in the Cg group. PARP-1 inhibitor via 5-AIQ treatment reverses the action significantly of all the previously mentioned effects. Moreover, histological examinations revealed anti-inflammatory effects of 5-AIQ, whereas Cg-group aggravated Cg-induced inflammation. Present findings demonstrate the potent anti-inflammatory action of the PARP-1 inhibitor in acute lung injury induced by carrageenan.

show abstract

Section: Discussionmentioning

confidence: 99%

The role of poly(ADP-ribose) polymerase-1 inhibitor in carrageenan-induced lung inflammation in mice

Ahmad

Zoheir

Ansari

et al. 2015

Molecular Immunology

View full text Add to dashboard Cite

show abstract

“…87 Exhaled breath condensate collected from ventilated infants can be used for diagnostic purposes using gas chromatography and mass spectrometry. 88 Increased end-tidal carbon monoxide (ETCO) 48 and exhaled nitric oxide (NO) 89 were also found to be higher in infants with BPD on postnatal day 14 and 28, respectively.…”

Section: Biomarkersmentioning

confidence: 99%

Biomarkers, Early Diagnosis, and Clinical Predictors of Bronchopulmonary Dysplasia

Lal

Ambalavanan

2015

Clinics in Perinatology

View full text Add to dashboard Cite

Bronchopulmonary Dysplasia (BPD) continues to be an important source of morbidity and mortality in premature neonates. The phenotype of BPD is extremely variable, and diagnosis is a clinical operational definition. A number of clinical and laboratory biomarkers have been proposed for the early identification of infants at higher risk of this disease, to characterize disease activity and severity and for determination of prognosis. Clinical prediction models for BPD have been developed using birth weight, gestational age, indicators of respiratory illness severity, and other clinical variables. Other biomarkers of BPD include those based on imaging of the lungs, lung function measures, and measurements of various analytes in different body fluids (blood, tracheal aspirates, exhaled breath condensates, urine, etc). Novel systems biology ‘omic’ based approaches including but not limited to genomics, proteomics, metabolomics and microbiomics are required for evaluating the multiple interacting cellular and molecular networks that control lung development and injury in BPD. Here we present a critical evaluation of the biomarker approaches studied in the diagnosis of BPD and highlight the future avenues for research in this field.

show abstract

Section: Chronic Lung Disease (Cld) Of Prematuritymentioning

confidence: 99%

“…Compared to controls, equal [134][135][136] or higher [137][138][139] FE NO was noted in infants and younger children with CLD. FE NO is particularly elevated in infants with moderate or severe CLD [138]. Although FE NO is not elevated in infants with CLD, calculated NO output V NO (nl/ min), by multiplying online flow rate (L/min) and FE NO (ppb), is reduced in infants with lower gestational age, higher clinical risk index for babies score, longer duration of oxygen therapy, postnatal treatment with corticosteroids, and more severe CLD [135].…”

Section: Chronic Lung Disease (Cld) Of Prematuritymentioning

confidence: 99%

Fractional Exhaled Nitric Oxide: Indications and Interpretation

Kim

Kercsmar

Davis

2014

Respiratory Medicine

View full text Add to dashboard Cite

Exhaled nitric oxide (NO) is a marker for eosinophilic airway inflammation. The correlations between fraction of exhaled NO (FE NO ) and eosinophils in blood, sputum, bronchoalveolar lavage, and mucosal biopsies of the airway have been well studied. A quantitative, noninvasive, and simple methodology has been developed to determine how best to assess FE NO as a measure of airway inflammation. FE NO measurement has been standardized by the American Thoracic Society/ European Respiratory Society (Am J Respir Crit Care Med 171(8): [912][913][914][915][916][917][918][919][920][921][922][923][924][925][926][927][928][929][930] 2005). The gold standard for measuring FE NO is the single-breath online method, which can be performed in young children from the age of 4-5 years. A chemiluminescencebased analyzer or a portable analyzer using an electrochemical sensor can be used to measure FE NO . Many studies have shown that FE NO has potential diagnostic and therapeutic roles in various respiratory diseases, particularly asthma. In asthma, FE NO is useful to diagnose and monitor eosinophilic airway inflammation, and predict steroid responsiveness. It also can be helpful in supporting the diagnosis of asthma and in guiding adjustment of anti-inflammatory medication. ATS Clinical Practice Guidelines have been published for interpretation and clinical applicability of FE NO (Dweik et al., 184(5):602-615, 2011). FE NO can provide additional information on underlying airway inflammation, and is complementary to respiratory symptoms, lung function tests, and bronchial provocation tests for asthma and other respiratory diseases in the clinical setting.

show abstract

Relation of exhaled nitric oxide levels to development of bronchopulmonary dysplasia

Abstract: Exhaled nitric oxide levels are raised in infants with established BPD, particularly in those developing moderate or severe BPD, and may reflect ongoing inflammation.

Cited by 28 publications

References 28 publications

The role of poly(ADP-ribose) polymerase-1 inhibitor in carrageenan-induced lung inflammation in mice

The role of poly(ADP-ribose) polymerase-1 inhibitor in carrageenan-induced lung inflammation in mice

Biomarkers, Early Diagnosis, and Clinical Predictors of Bronchopulmonary Dysplasia

Fractional Exhaled Nitric Oxide: Indications and Interpretation

Contact Info

Product

Resources

About